Childhood

Cancer
Survivor
Study
Treatment Exposure Status:
Expansion Cohort as of July 2014, Original
Cohort and Overall Cohort
Executive Committee Meeting
Memphis, TN
September 29th and 30th, 2014
Demographic and Cancer Treatment of Participant in the Expansion, Original and Overall Cohort
As of June 2014
Expansion Original Overall
Characteristic
cohort1 cohort2 cohort3
N % N % N %
Total 10102 100.0 14364 100.0 24466 100.0
Sex Male 5378 53.2 7717 53.7 13095 53.5
Female 4724 46.8 6647 46.3 11371 46.5
Race White 8035 79.5 12691 88.4 20726 84.7
Black 868 8.6 713 5.0 1581 6.5
Asian or Pacific Islander 204 2.0 167 1.2 371 1.5
Other 711 7.0 663 4.6 1374 5.6
Unknown 284 2.8 130 0.9 414 1.7
Hispanic Yes 1064 10.5 742 5.2 1806 7.4
No 8820 87.3 13066 91.0 21886 89.5
Unknown 218 2.2 556 3.9 774 3.2
Diagnosis Acute lymphoblastic leukemia 1832 18.1 4329 30.1 6161 25.2
Acute myeloid leukemia 516 5.1 356 2.5 872 3.6
Other leukemia 159 1.6 145 1.0 304 1.2
Astrocytomas 1414 14.0 1182 8.2 2596 10.6
Medulloblastoma, PNET 619 6.1 380 2.6 999 4.1
Other CNS tumors 422 4.2 314 2.2 736 3.0
Hodgkin lymphoma 1076 10.7 1927 13.4 3003 12.3
Non-Hodgkin lymphoma 919 9.1 1082 7.5 2001 8.2
Kidney tumors 914 9.0 1258 8.8 2172 8.9
Neuroblastoma 911 9.0 955 6.6 1866 7.6
Soft tissue sarcoma 465 4.6 1246 8.7 1711 7.0
Ewing sarcoma 311 3.1 405 2.8 716 2.9
Osteosarcoma 472 4.7 733 5.1 1205 4.9
Other bone tumors 47 0.5 52 0.4 99 0.4
Unknown 25 0.2 0 0.0 25 0.1
Age at diagnosis <1 849 8.4 1004 7.0 1853 7.6
1-3 2378 23.5 3639 25.3 6017 24.6
4-7 2187 21.6 3238 22.5 5425 22.2
8-10 1180 11.7 1575 11.0 2755 11.3
 11-14 1866 18.5 2417 16.8 4283 17.5
15-20 1596 15.8 2491 17.3 4087 16.7
Unknown 46 0.5 0 0.0 46 0.2
Status at 12/31/2007 Alive 9614 95.2 12323 85.8 21937 89.7
Dead 478 4.7 2023 14.1 2501 10.2
Unknown 10 0.1 18 0.1 28 0.1
Age at 12/31/2007 <20 4104 40.6 680 4.7 4784 19.6
20-29 4620 45.7 3968 27.6 8588 35.1
30-39 1352 13.4 5895 41.0 7247 29.6
40-49 16 0.2 3338 23.2 3354 13.7
50-59 0 0.0 465 3.2 465 1.9
Unknown 10 0.1 18 0.1 28 0.1
Year of diagnosis 1970-79 0 0.0 6613 46.0 6613 27.1
1980-89 2062 20.5 7751 54.0 9813 40.2
1990-99 7994 79.5 0 0.0 7994 32.7
Medical records available Yes 9806 97.1 12596 87.7 22402 91.6
No 296 2.9 1768 12.3 2064 8.4
Treatment modality Surgery only (S) 1127 11.2 909 6.3 2036 8.3
Chemo only (C) 1401 13.9 816 5.7 2217 9.1
Radiation only (R) 32 0.3 33 0.2 65 0.3
C+R 626 6.2 1459 10.2 2085 8.5
C+S 2859 28.3 2274 15.8 5133 21.0
R+S 466 4.6 1480 10.3 1946 8.0
C+R+S 3178 31.5 5554 38.7 8732 35.7
No treatment 45 0.4 12 0.1 57 0.2
Unknown treatment 368 3.6 1827 12.7 2195 9.0

1 15,247 survivors were eligible for the Expansion Cohort, including, 900 participants from The Dana-Farber Cancer Center.
2 20,690 eligible
3 35,937 eligible
 Treatment Exposure During First 5 Years After Primary Cancer by Cacner Diagnosis:
Expansion Cohort Participants with Complete Abstraction of Medical Records (N=9806) as of June 2014
Soft tissue
Agent Participants Leukemia CNS HD NHL Kidney Neuroblastoma sarcoma Bone cancer
N % N % N % N % N % N % N % N % N %
Total 9806 100.0 2453 100.0 2380 100.0 1057 100.0 887 100.0 887 100.0 882 100.0 445 100.0 815 100.0
Any radiation Yes 4303 43.9 820 33.4 1254 52.7 820 77.6 169 19.1 429 48.4 248 28.1 332 74.6 231 28.3
No 5433 55.4 1622 66.1 1102 46.3 226 21.4 712 80.3 453 51.1 627 71.1 112 25.2 579 71.0
Pending 70 0.7 11 0.4 24 1.0 11 1.0 6 0.7 5 0.6 7 0.8 1 0.2 5 0.6
Max dose to brain1 None 5434 61.4 1622 71.4 1102 53.4 227 24.7 712 84.3 453 56.2 627 77.2 112 30.3 579 76.2
1-19.9 Gy2 2212 25.0 525 23.1 49 2.4 690 75.2 113 13.4 351 43.5 161 19.8 162 43.8 161 21.2
20-29.9 Gy 154 1.7 110 4.8 4 0.2 1 0.1 10 1.2 1 0.1 16 2.0 10 2.7 2 0.3
30-49.9 Gy 135 1.5 16 0.7 54 2.6 0 0.0 9 1.1 1 0.1 5 0.6 38 10.3 12 1.6
>=50 Gy 913 10.3 0 0.0 855 41.4 0 0.0 1 0.1 0 0.0 3 0.4 48 13.0 6 0.8
Pending 958 . 180 . 316 . 139 . 42 . 81 . 70 . 75 . 55 .
None 5434 61.3 1622 71.3 1102 53.0 227 24.8 712 84.4 453 56.3 627 77.2 112 30.3 579 76.2
1-19.9 Gy2 2209 24.9 647 28.4 496 23.9 92 10.0 115 13.6 333 41.4 153 18.8 239 64.6 134 17.6
20-29.9 Gy 615 6.9 5 0.2 164 7.9 400 43.6 4 0.5 12 1.5 26 3.2 1 0.3 3 0.4
>=30 Gy 603 6.8 1 0.0 316 15.2 198 21.6 13 1.5 7 0.9 6 0.7 18 4.9 44 5.8
None 5434 61.3 1622 71.3 1102 53.0 227 24.8 712 84.4 453 56.3 627 77.2 112 30.3 579 76.2
Pending 945 . 178 . 302 . 140 . 43 . 82 . 70 . 75 . 55 .
Neck Yes 1594 18.0 270 11.9 491 23.6 644 70.2 53 6.3 11 1.4 68 8.4 34 9.2 23 3.0
No 7274 82.0 2007 88.1 1588 76.4 274 29.8 792 93.7 795 98.6 744 91.6 337 90.8 737 97.0
Pending 938 . 176 . 301 . 139 . 42 . 81 . 70 . 74 . 55 .
Abdomen Yes 1666 18.8 270 11.9 493 23.7 281 30.6 45 5.3 330 40.9 161 19.8 46 12.4 40 5.3
No 7201 81.2 2007 88.1 1586 76.3 637 69.4 800 94.7 476 59.1 651 80.2 325 87.6 719 94.7
Pending 939 . 176 . 301 . 139 . 42 . 81 . 70 . 74 . 56 .
Pelvis Yes 1444 16.3 265 11.6 488 23.5 172 18.7 46 5.4 224 27.8 99 12.2 84 22.6 66 8.7
No 7424 83.7 2012 88.4 1591 76.5 746 81.3 799 94.6 582 72.2 713 87.8 287 77.4 694 91.3
Pending 938 . 176 . 301 . 139 . 42 . 81 . 70 . 74 . 55 .
Limb Yes 457 5.2 200 8.8 3 0.1 58 6.3 35 4.1 2 0.2 68 8.4 26 7.0 65 8.6
No 8411 94.8 2077 91.2 2076 99.9 860 93.7 810 95.9 804 99.8 744 91.6 345 93.0 695 91.4
Pending 938 . 176 . 301 . 139 . 42 . 81 . 70 . 74 . 55 .
TBI Yes 299 3.4 198 8.7 2 0.1 4 0.4 24 2.8 0 0.0 60 7.4 1 0.3 10 1.3
No 8569 96.6 2079 91.3 2077 99.9 914 99.6 821 97.2 806 100.0 752 92.6 370 99.7 750 98.7
Pending 938 . 176 . 301 . 139 . 42 . 81 . 70 . 74 . 55 .
Any chemotherapy Yes 8091 82.5 2441 99.5 1138 47.8 972 92.0 883 99.5 868 97.9 555 62.9 444 99.8 790 96.9
 No 1675 17.1 7 0.3 1223 51.4 77 7.3 1 0.1 18 2.0 323 36.6 1 0.2 25 3.1
Pending 40 0.4 5 0.2 19 0.8 8 0.8 3 0.3 1 0.1 4 0.5 0 0.0 0 0.0
Alkylating agents (CED, None 4159 44.9 931 40.0 1559 68.9 281 28.7 61 7.3 768 87.5 337 42.0 90 21.6 132 17.3
mg/m2)1 >0 - <4000 1262 13.6 704 30.2 67 3.0 71 7.3 210 25.0 18 2.1 106 13.2 15 3.6 71 9.3
>=4000 - <8000 1448 15.6 289 12.4 108 4.8 411 42.0 334 39.8 24 2.7 179 22.3 13 3.1 90 11.8
>=8000 - <12000 1046 11.3 311 13.4 218 9.6 116 11.8 161 19.2 29 3.3 46 5.7 39 9.4 126 16.5
>=12000 - <16000 484 5.2 64 2.7 135 6.0 62 6.3 30 3.6 25 2.8 53 6.6 38 9.1 77 10.1
>=16000 - <20000 251 2.7 16 0.7 79 3.5 15 1.5 21 2.5 2 0.2 33 4.1 30 7.2 55 7.2
>=20000 619 6.7 13 0.6 96 4.2 23 2.3 23 2.7 12 1.4 48 6.0 192 46.0 212 27.8
Unknown 537 . 125 . 118 . 78 . 47 . 9 . 80 . 28 . 52 .
Anthracycline dose (mg/m2)1 None 4059 42.7 347 14.7 2336 99.1 138 13.6 106 12.4 425 48.7 392 46.8 279 64.4 36 4.6
>0 - <100 922 9.7 591 25.1 1 0.0 68 6.7 82 9.6 59 6.8 92 11.0 10 2.3 19 2.4
>=100 - <250 2762 29.1 951 40.3 8 0.3 651 64.3 435 51.1 282 32.3 293 35.0 39 9.0 103 13.2
>=250 - <400 1336 14.1 383 16.2 11 0.5 147 14.5 192 22.5 101 11.6 52 6.2 73 16.9 377 48.5
>=400 420 4.4 85 3.6 1 0.0 8 0.8 37 4.3 5 0.6 9 1.1 32 7.4 243 31.2
Unknown 307 . 96 . 23 . 45 . 35 . 15 . 44 . 12 . 37 .
1 Unknown doses are excluded from percentage calculations, 2 Includes scatter doses of radiation
 Treatment Exposure During First 5 Years After Primary Cancer by Cacner Diagnosis:
Expansion Cohort Participants with Complete Abstraction of Medical Records (N=9806) as of June 2014
Soft tissue Bone
Agent Participants Leukemia CNS HD NHL Kidney (Wilms) Neuroblastoma sarcoma cancer
N % N % N % N % N % N % N % N % N %
5-Azacytidine 108 1.1 107 4.4 1 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
ARA-G 3 0.0 2 0.1 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0
Bleomycin 780 8.0 0 0.0 2 0.1 668 63.7 18 2.0 0 0.0 0 0.0 7 1.6 85 10.4
Busulfan 149 1.5 140 5.7 1 0.0 0 0.0 1 0.1 2 0.2 0 0.0 1 0.2 4 0.5
Carboplatin 647 6.6 2 0.1 320 13.6 6 0.6 36 4.1 30 3.4 192 21.9 7 1.6 54 6.6
Carmustine (BCNU) 81 0.8 3 0.1 24 1.0 11 1.0 40 4.5 0 0.0 2 0.2 0 0.0 1 0.1
Chlorambucil 2 0.0 0 0.0 0 0.0 2 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Cisplatin 1353 13.9 0 0.0 540 22.9 17 1.6 38 4.3 0 0.0 366 41.7 33 7.4 359 44.0
Cyclophosphamide-All Routes 4445 45.5 1444 59.0 416 17.6 435 41.5 816 92.3 58 6.5 513 58.4 321 72.1 442 54.2
Cyclophosphamide-IV/IM 4348 44.5 1431 58.5 407 17.2 435 41.5 815 92.2 58 6.5 454 51.7 321 72.1 427 52.4
Cyclophosphamide-PO 166 1.7 11 0.4 7 0.3 0 0.0 1 0.1 0 0.0 127 14.5 0 0.0 20 2.5
Cytarabine 2962 30.3 2192 89.5 61 2.6 48 4.6 640 72.4 1 0.1 1 0.1 15 3.4 4 0.5
Dacarbazine (DTIC) 368 3.8 0 0.0 20 0.8 298 28.4 0 0.0 0 0.0 35 4.0 3 0.7 12 1.5
Dactinomycin 1480 15.2 13 0.5 39 1.7 1 0.1 5 0.6 811 91.5 6 0.7 379 85.2 226 27.7
Daunorubicin 1878 19.2 1645 67.2 0 0.0 4 0.4 222 25.1 2 0.2 3 0.3 0 0.0 2 0.2
Dexamethasone 1759 18.0 1109 45.3 181 7.7 84 8.0 165 18.7 16 1.8 36 4.1 42 9.4 126 15.5
Doxorubicin 4100 42.0 745 30.4 17 0.7 879 83.8 629 71.2 435 49.1 469 53.4 150 33.7 776 95.2
Epirubicin 1 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0
Etoposide (VP-16)-All Routes 2654 27.2 994 40.6 327 13.9 146 13.9 267 30.2 66 7.4 411 46.8 140 31.5 303 37.2
Etoposide (VP-16)-IV/IM 2631 26.9 989 40.4 315 13.3 144 13.7 267 30.2 66 7.4 409 46.6 139 31.2 302 37.1
Etoposide (VP-16)-PO 30 0.3 12 0.5 12 0.5 2 0.2 0 0.0 0 0.0 1 0.1 1 0.2 2 0.2
Fludarabine phosphate 31 0.3 30 1.2 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0
Fluorouracil (5-FU) 3 0.0 1 0.0 2 0.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Gemcitabine 1 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0
Gemtuzimab (Mylotarg) 1 0.0 0 0.0 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0
Gleevec 3 0.0 2 0.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.2 0 0.0
Hydroxyurea 162 1.7 70 2.9 59 2.5 0 0.0 32 3.6 0 0.0 1 0.1 0 0.0 0 0.0
Idarubicin 159 1.6 156 6.4 1 0.0 0 0.0 2 0.2 0 0.0 0 0.0 0 0.0 0 0.0
Ifosfamide 978 10.0 22 0.9 52 2.2 10 1.0 69 7.8 28 3.2 101 11.5 197 44.3 499 61.2
Irinotecan 6 0.1 0 0.0 3 0.1 0 0.0 0 0.0 0 0.0 2 0.2 1 0.2 0 0.0
L-Asparaginase 2054 21.0 1785 72.9 0 0.0 4 0.4 264 29.9 0 0.0 1 0.1 0 0.0 0 0.0
Lomustine (CCNU) 357 3.7 0 0.0 341 14.4 15 1.4 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0
Mechlorethamine (N. Mustard) 328 3.4 1 0.0 17 0.7 297 28.3 3 0.3 0 0.0 10 1.1 0 0.0 0 0.0
Melphalan-All Routes 127 1.3 5 0.2 4 0.2 1 0.1 0 0.0 3 0.3 85 9.7 12 2.7 17 2.1
Melphalan-IV/IM 121 1.2 4 0.2 3 0.1 1 0.1 0 0.0 3 0.3 81 9.2 12 2.7 17 2.1
Melphalan-PO 1 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0
Mercaptopurine (6-MP) 1808 18.5 1596 65.2 2 0.1 1 0.1 207 23.4 1 0.1 1 0.1 0 0.0 0 0.0
Methotrexate-All Routes 3411 34.9 2004 81.9 13 0.6 157 15.0 800 90.5 1 0.1 6 0.7 28 6.3 402 49.3
Methotrexate-IM 492 5.0 463 18.9 0 0.0 0 0.0 28 3.2 0 0.0 1 0.1 0 0.0 0 0.0
Methotrexate-IT/Ommaya 2649 27.1 1900 77.6 2 0.1 4 0.4 718 81.2 1 0.1 2 0.2 16 3.6 6 0.7
Methotrexate-IV 2434 24.9 1264 51.6 9 0.4 153 14.6 594 67.2 0 0.0 5 0.6 12 2.7 397 48.7
Methotrexate-PO 924 9.5 815 33.3 3 0.1 1 0.1 105 11.9 0 0.0 0 0.0 0 0.0 0 0.0
Mitoxantrone 97 1.0 68 2.8 0 0.0 25 2.4 4 0.5 0 0.0 0 0.0 0 0.0 0 0.0
Prednisone 3174 32.5 1662 67.9 55 2.3 743 70.8 694 78.5 7 0.8 4 0.5 3 0.7 6 0.7
Procarbazine 832 8.5 0 0.0 139 5.9 687 65.5 6 0.7 0 0.0 0 0.0 0 0.0 0 0.0
Taxol 2 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 0.2 0 0.0 0 0.0
Taxotere 4 0.0 0 0.0 3 0.1 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Temozolomide 18 0.2 0 0.0 15 0.6 0 0.0 0 0.0 0 0.0 3 0.3 0 0.0 0 0.0
Teniposide (VM-26) 325 3.3 261 10.7 0 0.0 1 0.1 31 3.5 0 0.0 29 3.3 0 0.0 3 0.4
Thioguanine (6-TG) 1151 11.8 986 40.3 36 1.5 0 0.0 129 14.6 0 0.0 0 0.0 0 0.0 0 0.0
Thiotepa-All Routes 99 1.0 16 0.7 31 1.3 2 0.2 22 2.5 4 0.5 18 2.1 1 0.2 5 0.6
Thiotepa-IT 2 0.0 1 0.0 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0
Thiotepa-IV/IM 97 1.0 15 0.6 31 1.3 2 0.2 21 2.4 4 0.5 18 2.1 1 0.2 5 0.6
Topotecan 60 0.6 1 0.0 26 1.1 0 0.0 1 0.1 2 0.2 19 2.2 6 1.3 5 0.6
Vinblastine 839 8.6 4 0.2 2 0.1 826 78.7 6 0.7 0 0.0 0 0.0 1 0.2 0 0.0
Vincristine 6255 64.0 1926 78.7 854 36.2 760 72.4 868 98.2 858 96.8 153 17.4 440 98.9 396 48.6
Vinorelbine 5 0.1 0 0.0 1 0.0 3 0.3 0 0.0 1 0.1 0 0.0 0 0.0 0 0.0
ATG 20 0.2 18 0.7 0 0.0 0 0.0 1 0.1 0 0.0 1 0.1 0 0.0 0 0.0
Cyclosporine (CSA) 95 1.0 81 3.3 2 0.1 0 0.0 8 0.9 0 0.0 3 0.3 0 0.0 1 0.1
Rituximab (Rituxan) 5 0.1 1 0.0 0 0.0 0 0.0 4 0.5 0 0.0 0 0.0 0 0.0 0 0.0
Tacrolimus 8 0.1 6 0.2 0 0.0 0 0.0 1 0.1 1 0.1 0 0.0 0 0.0 0 0.0
Erythropoietin (EPO) 17 0.2 4 0.2 0 0.0 0 0.0 1 0.1 1 0.1 3 0.3 5 1.1 3 0.4
GCSF 1133 11.6 227 9.3 144 6.1 64 6.1 208 23.5 28 3.2 133 15.1 131 29.4 198 24.3
GMCSF 45 0.5 15 0.6 5 0.2 3 0.3 3 0.3 0 0.0 14 1.6 2 0.4 3 0.4
Interferon 23 0.2 16 0.7 2 0.1 1 0.1 2 0.2 0 0.0 2 0.2 0 0.0 0 0.0
Interleukin-2 23 0.2 18 0.7 0 0.0 1 0.1 1 0.1 0 0.0 3 0.3 0 0.0 0 0.0
Mesna 1080 11.1 97 4.0 184 7.8 19 1.8 132 14.9 23 2.6 108 12.3 166 37.3 351 43.1
Retinoic Acid 111 1.1 35 1.4 2 0.1 0 0.0 0 0.0 0 0.0 74 8.4 0 0.0 0 0.0
Zinecard (Dexrazoxane) 37 0.4 10 0.4 0 0.0 10 1.0 6 0.7 0 0.0 1 0.1 0 0.0 10 1.2
 Treatment Exposure During First 5 Years after Primary Cancer by Cancer Diagnosis:
Original Cohort Participants with Complete Abstraction of Medical Records (N=12596) as of June 2014
Soft tissue
Agent Participants Leukemia CNS HD NHL Kidney (Wilms) Neuroblastoma sarcoma Bone cancer
N % N % N % N % N % N % N % N % N %
Total 12596 100.0 4278 100.0 1660 100.0 1675 100.0 922 100.0 1086 100.0 835 100.0 1096 100.0 1044 100.0
Any radiation Yes 8550 67.9 2958 69.1 1191 71.7 1577 94.1 633 68.7 702 64.6 411 49.2 695 63.4 383 36.7
No 4013 31.9 1303 30.5 462 27.8 98 5.9 288 31.2 383 35.3 422 50.5 398 36.3 659 63.1
Pending 33 0.3 17 0.4 7 0.4 0 0.0 1 0.1 1 0.1 2 0.2 3 0.3 2 0.2
None 4131 33.9 1370 33.2 480 30.6 107 6.6 290 32.3 386 36.6 425 51.8 404 38.1 669 65.5
1-19.9 Gy 2 5110 42.0 1328 32.2 45 2.9 1494 92.0 413 46.0 669 63.4 362 44.1 466 44.0 333 32.6
20-29.9 Gy 1434 11.8 1264 30.7 5 0.3 7 0.4 141 15.7 0 0.0 8 1.0 8 0.8 1 0.1
30-49.9 Gy 489 4.0 153 3.7 185 11.8 15 0.9 43 4.8 1 0.1 13 1.6 69 6.5 10 1.0
>=50 Gy 1008 8.3 8 0.2 854 54.4 1 0.1 11 1.2 0 0.0 12 1.5 113 10.7 9 0.9
Pending 424 . 155 . 91 . 51 . 24 . 30 . 15 . 36 . 22 .
Max dose to chest1 None 4132 34.0 1370 33.2 480 30.5 107 6.6 290 32.3 386 36.6 425 51.9 404 38.2 670 65.8
1-19.9 Gy 2 5482 45.1 2540 61.5 672 42.7 163 10.1 410 45.7 577 54.6 288 35.2 561 53.1 271 26.6
20-29.9 Gy 778 6.4 204 4.9 98 6.2 248 15.4 89 9.9 67 6.3 60 7.3 5 0.5 7 0.7
>=30 Gy 1770 14.6 14 0.3 322 20.5 1097 67.9 108 12.0 26 2.5 46 5.6 87 8.2 70 6.9
None 4132 34.0 1370 33.2 480 30.5 107 6.6 290 32.3 386 36.6 425 51.9 404 38.2 670 65.8
Pending 434 . 150 . 88 . 60 . 25 . 30 . 16 . 39 . 26 .
Neck Yes 2967 24.3 559 13.5 443 28.1 1441 88.6 275 30.6 17 1.6 93 11.3 120 11.3 19 1.9
No 9226 75.7 3577 86.5 1132 71.9 185 11.4 624 69.4 1039 98.4 727 88.7 939 88.7 1003 98.1
Pending 403 . 142 . 85 . 49 . 23 . 30 . 15 . 37 . 22 .
Abdomen Yes 3222 26.4 563 13.6 436 27.7 980 60.3 201 22.3 664 62.8 231 28.2 96 9.1 51 5.0
No 8972 73.6 3573 86.4 1139 72.3 645 39.7 699 77.7 394 37.2 588 71.8 963 90.9 971 95.0
Pending 402 . 142 . 85 . 50 . 22 . 28 . 16 . 37 . 22 .
Pelvis Yes 2629 21.6 558 13.5 424 26.9 640 39.4 197 21.9 383 36.2 150 18.3 186 17.6 91 8.9
No 9565 78.4 3578 86.5 1151 73.1 985 60.6 703 78.1 675 63.8 669 81.7 873 82.4 931 91.1
Pending 402 . 142 . 85 . 50 . 22 . 28 . 16 . 37 . 22 .
Limb Yes 320 2.7 162 3.9 0 0.0 16 1.0 36 4.1 0 0.0 16 2.0 43 4.4 47 5.2
No 11617 97.3 3960 96.1 1574 100.0 1606 99.0 839 95.9 1053 100.0 799 98.0 936 95.6 850 94.8
Pending 659 . 156 . 86 . 53 . 47 . 33 . 20 . 117 . 147 .
TBI Yes 196 1.6 157 3.8 0 0.0 3 0.2 14 1.6 0 0.0 16 2.0 3 0.3 3 0.3
No 11990 98.4 3976 96.2 1575 100.0 1621 99.8 884 98.4 1056 100.0 803 98.0 1056 99.7 1019 99.7
Pending 410 . 145 . 85 . 51 . 24 . 30 . 16 . 37 . 22 .
Any chemotherapy Yes 10140 80.5 4276 100.0 500 30.1 1122 67.0 872 94.6 1069 98.4 495 59.3 867 79.1 939 89.9
 No 2438 19.4 2 0.0 1153 69.5 548 32.7 49 5.3 17 1.6 338 40.5 226 20.6 105 10.1
Pending 18 0.1 0 0.0 7 0.4 5 0.3 1 0.1 0 0.0 2 0.2 3 0.3 0 0.0
Alkylating agents (CED, None 6011 52.6 1987 50.8 1283 81.9 629 45.6 112 13.7 985 92.0 346 45.6 353 35.9 316 33.7
mg/m2)1 >0 - <4000 1335 11.7 894 22.9 35 2.2 39 2.8 146 17.8 21 2.0 57 7.5 55 5.6 88 9.4
>=4000 - <8000 1216 10.6 407 10.4 36 2.3 140 10.2 161 19.7 38 3.5 118 15.5 86 8.8 230 24.5
>=8000 - <12000 1082 9.5 293 7.5 83 5.3 253 18.4 169 20.6 8 0.7 74 9.7 120 12.2 82 8.7
>=12000 - <16000 760 6.7 113 2.9 82 5.2 201 14.6 108 13.2 4 0.4 58 7.6 106 10.8 88 9.4
>=16000 - <20000 456 4.0 91 2.3 22 1.4 52 3.8 68 8.3 5 0.5 38 5.0 113 11.5 67 7.1
>=20000 564 4.9 124 3.2 26 1.7 64 4.6 55 6.7 10 0.9 68 9.0 149 15.2 68 7.2
Unknown 1172 . 369 . 93 . 297 . 103 . 15 . 76 . 114 . 105 .
Anthracycline dose (mg/m2)1 None 7594 63.0 2214 54.6 1643 99.6 1281 79.0 400 46.6 638 60.6 605 74.1 623 59.2 190 20.1
>0 - <100 434 3.6 313 7.7 0 0.0 21 1.3 18 2.1 16 1.5 27 3.3 22 2.1 17 1.8
>=100 - <250 1382 11.5 645 15.9 4 0.2 159 9.8 144 16.8 162 15.4 107 13.1 84 8.0 77 8.2
>=250 - <400 1605 13.3 492 12.1 2 0.1 145 8.9 196 22.8 217 20.6 50 6.1 175 16.6 328 34.8
>=400 1034 8.6 389 9.6 1 0.1 16 1.0 101 11.8 19 1.8 28 3.4 149 14.2 331 35.1
Unknown 547 . 225 . 10 . 53 . 63 . 34 . 18 . 43 . 101 .

1 Unknown doses are excluded from percentage calculations, 2 Includes scatter doses of radiation
 Exposure to Specific Treatment Agents During Frist 5 Years after Primary Cancer by Cancer Diagnosis:
Original Cohort Participants with Complete Abstraction of Medical Records (N=12596) as of June 2014
Soft tissue Bone
Agent Participants Leukemia CNS HD NHL Kidney (Wilms) Neuroblastoma sarcoma cancer
N % N % N % N % N % N % N % N % N %
5-Azacytidine 184 1.5 182 4.3 0 0.0 0 0.0 2 0.2 0 0.0 0 0.0 0 0.0 0 0.0
Bleomycin 756 6.0 5 0.1 8 0.5 373 22.3 56 6.1 2 0.2 3 0.4 48 4.4 261 25.0
Busulfan 47 0.4 39 0.9 0 0.0 4 0.2 1 0.1 0 0.0 2 0.2 0 0.0 1 0.1
Carboplatin 76 0.6 4 0.1 37 2.2 2 0.1 0 0.0 4 0.4 9 1.1 5 0.5 15 1.4
Carmustine (BCNU) 516 4.1 197 4.6 42 2.5 51 3.1 188 20.4 0 0.0 2 0.2 14 1.3 22 2.1
Chlorambucil 76 0.6 1 0.0 0 0.0 49 2.9 5 0.5 0 0.0 1 0.1 12 1.1 8 0.8
Cisplatin 739 5.9 8 0.2 165 10.0 21 1.3 14 1.5 21 1.9 111 13.3 113 10.3 286 27.4
Cyclophosphamide-All Routes 5696 45.3 2369 55.4 119 7.2 383 22.9 799 86.8 94 8.7 480 57.6 732 67.0 720 69.0
Cyclophosphamide-IV/IM 5064 40.3 2073 48.5 108 6.5 370 22.2 776 84.3 90 8.3 360 43.2 619 56.6 668 64.0
Cyclophosphamide-PO 1018 8.1 411 9.6 13 0.8 21 1.3 44 4.8 5 0.5 226 27.1 192 17.6 106 10.2
Cytarabine 3132 24.9 2497 58.4 100 6.0 40 2.4 413 44.8 1 0.1 17 2.0 53 4.8 11 1.1
Dacarbazine (DTIC) 616 4.9 4 0.1 39 2.4 275 16.5 4 0.4 4 0.4 164 19.7 88 8.1 38 3.6
Dactinomycin 2533 20.1 64 1.5 41 2.5 4 0.2 21 2.3 1063 97.9 12 1.4 785 71.8 543 52.0
Daunorubicin 1689 13.4 1416 33.1 1 0.1 0 0.0 262 28.4 0 0.0 5 0.6 3 0.3 2 0.2
Dexamethasone 1015 8.1 585 13.7 129 7.8 57 3.4 73 7.9 6 0.6 20 2.4 47 4.3 98 9.4
Doxorubicin 4074 32.4 1319 30.8 14 0.8 428 25.6 295 32.0 452 41.6 226 27.1 481 44.0 859 82.3
Epirubicin 3 0.0 1 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 1 0.1
Etoposide (VP-16)-All Routes 861 6.8 502 11.7 59 3.6 60 3.6 42 4.6 33 3.0 22 2.6 82 7.5 61 5.8
Etoposide (VP-16)-IV/IM 840 6.7 498 11.6 54 3.3 53 3.2 41 4.5 33 3.0 19 2.3 81 7.4 61 5.8
Etoposide (VP-16)-PO 39 0.3 12 0.3 7 0.4 8 0.5 1 0.1 1 0.1 3 0.4 2 0.2 5 0.5
Fludarabine phosphate 4 0.0 3 0.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 0 0.0
Fluorouracil (5-FU) 71 0.6 4 0.1 14 0.8 3 0.2 2 0.2 5 0.5 8 1.0 11 1.0 24 2.3
Hydroxyurea 521 4.1 193 4.5 125 7.6 1 0.1 187 20.3 0 0.0 11 1.3 3 0.3 1 0.1
Idarubicin 10 0.1 8 0.2 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 0 0.0
Ifosfamide 190 1.5 28 0.7 15 0.9 7 0.4 5 0.5 20 1.8 7 0.8 44 4.0 64 6.1
L-Asparaginase 3946 31.4 3646 85.2 3 0.2 0 0.0 297 32.2 0 0.0 0 0.0 0 0.0 0 0.0
Lomustine (CCNU) 498 4.0 16 0.4 278 16.8 166 9.9 32 3.5 0 0.0 1 0.1 1 0.1 4 0.4
Mechlorethamine (N. Mustard) 791 6.3 7 0.2 48 2.9 653 39.1 21 2.3 1 0.1 36 4.3 15 1.4 10 1.0
Melphalan-All Routes 135 1.1 4 0.1 3 0.2 39 2.3 1 0.1 0 0.0 33 4.0 8 0.7 47 4.5
Melphalan-IV/IM 89 0.7 3 0.1 1 0.1 3 0.2 0 0.0 0 0.0 29 3.5 8 0.7 45 4.3
Melphalan-PO 45 0.4 1 0.0 1 0.1 36 2.2 1 0.1 0 0.0 5 0.6 0 0.0 1 0.1
Mercaptopurine (6-MP) 3970 31.6 3686 86.2 6 0.4 2 0.1 273 29.6 0 0.0 0 0.0 3 0.3 0 0.0
Methotrexate-All Routes 5677 45.1 4129 96.5 53 3.2 30 1.8 791 85.9 0 0.0 12 1.4 111 10.2 551 52.8
Methotrexate-IM 485 3.9 445 10.4 0 0.0 0 0.0 33 3.6 0 0.0 0 0.0 2 0.2 5 0.5
Methotrexate-IT/Ommaya 4614 36.7 3831 89.6 27 1.6 2 0.1 694 75.4 0 0.0 6 0.7 46 4.2 8 0.8
Methotrexate-IV 2754 21.9 1725 40.3 20 1.2 21 1.3 387 42.0 0 0.0 6 0.7 60 5.5 535 51.2
Methotrexate-PO 3504 27.9 3098 72.4 9 0.5 8 0.5 378 41.0 0 0.0 0 0.0 4 0.4 7 0.7
Mitoxantrone 13 0.1 7 0.2 0 0.0 2 0.1 0 0.0 0 0.0 1 0.1 2 0.2 1 0.1
Prednisone 5872 46.7 3981 93.1 163 9.9 862 51.6 804 87.3 8 0.7 15 1.8 22 2.0 17 1.6
Procarbazine 1287 10.2 2 0.0 227 13.7 1034 61.9 16 1.7 0 0.0 6 0.7 1 0.1 1 0.1
Taxol 2 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 1 0.1
Teniposide (VM-26) 650 5.2 484 11.3 12 0.7 4 0.2 47 5.1 5 0.5 87 10.4 8 0.7 3 0.3
Thioguanine (6-TG) 1183 9.4 920 21.5 30 1.8 3 0.2 229 24.9 1 0.1 0 0.0 0 0.0 0 0.0
Thiotepa-All Routes 66 0.5 15 0.4 6 0.4 35 2.1 2 0.2 2 0.2 1 0.1 1 0.1 4 0.4
Thiotepa-IT 5 0.0 4 0.1 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0
Thiotepa-IV/IM 57 0.5 9 0.2 6 0.4 35 2.1 1 0.1 2 0.2 0 0.0 1 0.1 3 0.3
Topotecan 5 0.0 2 0.0 2 0.1 0 0.0 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0
Vinblastine 585 4.7 24 0.6 4 0.2 506 30.3 23 2.5 9 0.8 7 0.8 6 0.5 6 0.6
Vincristine 9034 71.8 4092 95.7 388 23.5 926 55.4 835 90.7 993 91.4 308 37.0 808 73.9 684 65.5
Vinorelbine 1 0.0 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Cyclosporine (CSA) 1 0.0 1 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
GCSF 7 0.1 4 0.1 1 0.1 0 0.0 0 0.0 1 0.1 1 0.1 0 0.0 0 0.0
GMCSF 3 0.0 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0 0 0.0 0 0.0 2 0.2
Interferon 17 0.1 10 0.2 0 0.0 2 0.1 1 0.1 1 0.1 1 0.1 1 0.1 1 0.1
Interleukin-2 5 0.0 2 0.0 0 0.0 1 0.1 1 0.1 1 0.1 0 0.0 0 0.0 0 0.0
Mesna 26 0.2 7 0.2 5 0.3 1 0.1 0 0.0 3 0.3 1 0.1 5 0.5 4 0.4
Retinoic Acid 6 0.0 3 0.1 1 0.1 1 0.1 0 0.0 0 0.0 1 0.1 0 0.0 0 0.0
 Exposure to Specific Treatment Agents During First 5 Years after Primary Cancer by Cancer Diagnosis:
Overall Cohort Participants with Complete Abstraction of Medical Records (N=22402) as of June 2014
Soft tissue
Agent Participants Leukemia CNS HD NHL Kidney (Wilms) Neuroblastoma sarcoma Bone cancer
N % N % N % N % N % N % N % N % N %
Total 22402 100.0 6731 100.0 4040 100.0 2732 100.0 1809 100.0 1973 100.0 1717 100.0 1541 100.0 1859 100.0
Any radiation Yes 12853 57.4 3778 56.1 2445 60.5 2397 87.7 802 44.3 1131 57.3 659 38.4 1027 66.6 614 33.0
No 9446 42.2 2925 43.5 1564 38.7 324 11.9 1000 55.3 836 42.4 1049 61.1 510 33.1 1238 66.6
Pending 103 0.5 28 0.4 31 0.8 11 0.4 7 0.4 6 0.3 9 0.5 4 0.3 7 0.4
Max dose to brain1 None 9565 45.5 2992 46.8 1582 43.5 334 13.1 1002 57.5 839 45.1 1052 64.5 516 36.1 1248 70.0
1-19.9 Gy2 7322 34.8 1853 29.0 94 2.6 2184 85.9 526 30.2 1020 54.8 523 32.0 628 43.9 494 27.7
20-29.9 Gy 1588 7.6 1374 21.5 9 0.2 8 0.3 151 8.7 1 0.1 24 1.5 18 1.3 3 0.2
30-49.9 Gy 624 3.0 169 2.6 239 6.6 15 0.6 52 3.0 2 0.1 18 1.1 107 7.5 22 1.2
>=50 Gy 1921 9.1 8 0.1 1709 47.0 1 0.0 12 0.7 0 0.0 15 0.9 161 11.3 15 0.8
Pending 1382 . 335 . 407 . 190 . 66 . 111 . 85 . 111 . 77 .
Max dose to chest1 None 9566 45.5 2992 46.7 1582 43.3 334 13.2 1002 57.6 839 45.1 1052 64.5 516 36.2 1249 70.2
1-19.9 Gy2 7691 36.6 3187 49.8 1168 32.0 255 10.1 525 30.2 910 48.9 441 27.0 800 56.1 405 22.8
20-29.9 Gy 1393 6.6 209 3.3 262 7.2 648 25.6 93 5.3 79 4.2 86 5.3 6 0.4 10 0.6
>=30 Gy 2373 11.3 15 0.2 638 17.5 1295 51.1 121 7.0 33 1.8 52 3.2 105 7.4 114 6.4
Pending 1379 . 328 . 390 . 200 . 68 . 112 . 86 . 114 . 81 .
Neck Yes 4561 21.7 829 12.9 934 25.6 2085 82.0 328 18.8 28 1.5 161 9.9 154 10.8 42 2.4
No 16500 78.3 5584 87.1 2720 74.4 459 18.0 1416 81.2 1834 98.5 1471 90.1 1276 89.2 1740 97.6
Pending 1341 . 318 . 386 . 188 . 65 . 111 . 85 . 111 . 77 .
Abdomen Yes 4888 23.2 833 13.0 929 25.4 1261 49.6 246 14.1 994 53.3 392 24.0 142 9.9 91 5.1
No 16173 76.8 5580 87.0 2725 74.6 1282 50.4 1499 85.9 870 46.7 1239 76.0 1288 90.1 1690 94.9
Pending 1341 . 318 . 386 . 189 . 64 . 109 . 86 . 111 . 78 .
Pelvis Yes 4073 19.3 823 12.8 912 25.0 812 31.9 243 13.9 607 32.6 249 15.3 270 18.9 157 8.8
No 16989 80.7 5590 87.2 2742 75.0 1731 68.1 1502 86.1 1257 67.4 1382 84.7 1160 81.1 1625 91.2
Pending 1340 . 318 . 386 . 189 . 64 . 109 . 86 . 111 . 77 .
Limb Yes 777 3.7 362 5.7 3 0.1 74 2.9 71 4.1 2 0.1 84 5.2 69 5.1 112 6.8
No 20028 96.3 6037 94.3 3650 99.9 2466 97.1 1649 95.9 1857 99.9 1543 94.8 1281 94.9 1545 93.2
Pending 1597 . 332 . 387 . 192 . 89 . 114 . 90 . 191 . 202 .
TBI Yes 495 2.4 355 5.5 2 0.1 7 0.3 38 2.2 0 0.0 76 4.7 4 0.3 13 0.7
No 20559 97.6 6055 94.5 3652 99.9 2535 99.7 1705 97.8 1862 100.0 1555 95.3 1426 99.7 1769 99.3
Pending 1348 . 321 . 386 . 190 . 66 . 111 . 86 . 111 . 77 .
Any chemotherapy Yes 18231 81.4 6717 99.8 1638 40.5 2094 76.6 1755 97.0 1937 98.2 1050 61.2 1311 85.1 1729 93.0
 No 4113 18.4 9 0.1 2376 58.8 625 22.9 50 2.8 35 1.8 661 38.5 227 14.7 130 7.0
Pending 58 0.3 5 0.1 26 0.6 13 0.5 4 0.2 1 0.1 6 0.3 3 0.2 0 0.0
Alkylating agents (CED, None 10170 49.1 2918 46.8 2842 74.2 910 38.6 173 10.4 1753 89.9 683 43.8 443 31.7 448 26.3
mg/m2)1 >0 - <4000 2597 12.6 1598 25.6 102 2.7 110 4.7 356 21.5 39 2.0 163 10.4 70 5.0 159 9.3
>=4000 - <8000 2664 12.9 696 11.2 144 3.8 551 23.4 495 29.8 62 3.2 297 19.0 99 7.1 320 18.8
>=8000 - <12000 2128 10.3 604 9.7 301 7.9 369 15.7 330 19.9 37 1.9 120 7.7 159 11.4 208 12.2
>=12000 - <16000 1244 6.0 177 2.8 217 5.7 263 11.2 138 8.3 29 1.5 111 7.1 144 10.3 165 9.7
>=16000 - <20000 707 3.4 107 1.7 101 2.6 67 2.8 89 5.4 7 0.4 71 4.5 143 10.2 122 7.2
>=20000 1183 5.7 137 2.2 122 3.2 87 3.7 78 4.7 22 1.1 116 7.4 341 24.4 280 16.5
Unknown 1709 . 494 . 211 . 375 . 150 . 24 . 156 . 142 . 157 .
Anthracycline dose None 11653 54.1 2561 40.0 3979 99.3 1419 53.9 506 29.6 1063 55.2 997 60.2 902 60.7 226 13.1
(mg/m2)1 >0 - <100 1356 6.3 904 14.1 1 0.0 89 3.4 100 5.8 75 3.9 119 7.2 32 2.2 36 2.1
>=100 - <250 4144 19.2 1596 24.9 12 0.3 810 30.8 579 33.8 444 23.1 400 24.2 123 8.3 180 10.5
>=250 - <400 2941 13.6 875 13.7 13 0.3 292 11.1 388 22.7 318 16.5 102 6.2 248 16.7 705 41.0
>=400 1454 6.7 474 7.4 2 0.0 24 0.9 138 8.1 24 1.2 37 2.2 181 12.2 574 33.4
Unknown 854 . 321 . 33 . 98 . 98 . 49 . 62 . 55 . 138 .

1 Unknown doses are excluded from percentage calculations, 2 Includes scatter doses of radiation